TABLE 2.

Correlation analyses between sNfL levels in treatment‐naïve patients with CIDP at pre‐IVIg and disease activity, treatment responses, and clinical features

		sNfL (Pre‐IVIg)
CIDP subtype, n typical : atypical	7:4	p = .257
Age, year a	59.6 (53.5–71.1)	r = 0.30 p =.370
Disease duration, week a	16.0 (8.0–28.0)	r = −0.70 p = .016
ONLS a	5.0 (3.0–6.0)	r = 0.49 p =.122
Grip strength; kg, mean (SD)	12.3 (8.3)	r = −0.31 p = .347
MRC sum score a	54.0 (52.5–56.5)	r = −0.38 p = .250
Summated distal CMAP negative peak area, mVms a	30.3 (24.2–61.1)	r = −0.28 p = .401

Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; CMAP, compound muscle action potential; IQR, interquartile range; IVIg, intravenous immunoglobulin; MRC sum score, Medical Research Council sum score; ONLS, Overall Neuropathy Limitations Scale; SD, standard deviation; sNfL, serum neurofilament light chain.

^aMedian (IQR).